- cafead Sep 14, 2021 at 11:02: AM
via The FDA’s recent approval of Biogen’s Aduhelm has provided a spark plug for neuroscience research across the biopharma spectrum with investors more likely than ever to jump on board. A Chicago biotech now has its own clutch of blue-chip backers to pursue drugs across a range of indications — and it all started from a close colleague’s own diagnosis and search for a cure.
article source
article source